Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Recruiting · NCT04643002 · Registry updated 2026-06-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | Plasma Cell Myeloma Refractory | Recruiting | Phase 1 / Phase 2 | 2026-06-16 | NCT04643002 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sanofi | 254 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Puerto Rico Medical Research Center- Site Number : 8400005 | Hato Rey | Puerto Rico | 1 |
| Roswell Park Cancer Institute- Site Number : 8400008 | Buffalo | United States | 1 |
| The Ohio State University- Site Number : 8400012 | Columbus | United States | 1 |
| University of Illinois-Chicago - College of Medicine- Site Number : 8400007 | Chicago | United States | 1 |
| University of Michigan Health System - Ann Arbor- Site Number : 8400004 | Ann Arbor | United States | 2 |
| Winship Cancer Institute of Emory University- Site Number : 8400010 | Atlanta | United States | 1 |